tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kostas Biliouris, 40 are a BUY (68.97%), 18 are a HOLD (31.03%).
Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 33.49% that have a potential upside of 38.43% achieved within 122 days.
Kostas Biliouris’s has documented 125 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 21-Sep-2025.
Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$41
$15.02 (57.81%)
$30
10 days ago
(08-Oct-2025)
2/4 (50%)
$13.13 (47.11%)
147
Hold
$21
$-4.98 (-19.17%)
$25
2 months 13 days ago
(05-Aug-2025)
11/11 (100%)
$2.7 (14.75%)
145
Buy
$55
$29.02 (111.70%)
$78
5 months 12 days ago
(06-May-2025)
0/4 (0%)
$38.77 (238.88%)
Buy
$70
$44.02 (169.44%)
$105
5 months 12 days ago
(06-May-2025)
0/3 (0%)
$53.77 (331.30%)
$40
$14.02 (53.96%)
$57
5 months 26 days ago
(22-Apr-2025)
2/5 (40%)
$20.13 (101.31%)
4
Which stock is Kostas Biliouris is most bullish on?
Which stock is Kostas Biliouris is most reserved on?
What Year was the first public recommendation made by Kostas Biliouris?
